Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.17)
# 1,522
Out of 4,667 analysts
104
Total ratings
48.28%
Success rate
-9.34%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $86 | $11.16 | +670.61% | 6 | Nov 19, 2024 | |
| GHRS GH Research | Maintains: Buy | $31 → $28 | $10.95 | +155.71% | 4 | Nov 18, 2024 | |
| ATAI Atai Life Sciences | Maintains: Buy | $11 | $1.59 | +591.82% | 1 | Nov 18, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $23 | $8.97 | +156.41% | 4 | Nov 14, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 | $5.36 | +161.19% | 4 | Nov 14, 2024 | |
| CLNN Clene | Maintains: Buy | $86 → $83 | $4.09 | +1,929.34% | 5 | Nov 14, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $14 | $7.52 | +86.17% | 1 | Sep 16, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $7 | $0.59 | +1,090.48% | 6 | Aug 30, 2024 | |
| CMPS COMPASS Pathways | Maintains: Buy | $50 → $48 | $4.66 | +930.04% | 2 | Aug 2, 2024 | |
| CRVO CervoMed | Maintains: Buy | $65 | $9.64 | +574.27% | 3 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $113 | $85.64 | +31.95% | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $1 | $0.31 | +227.87% | 4 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $11.31 | +76.83% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $154 → $164 | $123.29 | +33.02% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $26 | $6.54 | +297.55% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $21 → $17 | $4.91 | +246.23% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $16.27 | +102.83% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $305 | $156.00 | +95.51% | 19 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $46.83 | +220.31% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $17.03 | - | 2 | Jan 31, 2017 |
Cybin
Nov 19, 2024
Maintains: Buy
Price Target: $86
Current: $11.16
Upside: +670.61%
GH Research
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $10.95
Upside: +155.71%
Atai Life Sciences
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $1.59
Upside: +591.82%
Zevra Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $8.97
Upside: +156.41%
Voyager Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $14
Current: $5.36
Upside: +161.19%
Clene
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $4.09
Upside: +1,929.34%
Mind Medicine (MindMed)
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.52
Upside: +86.17%
BioXcel Therapeutics
Aug 30, 2024
Maintains: Buy
Price Target: $7
Current: $0.59
Upside: +1,090.48%
COMPASS Pathways
Aug 2, 2024
Maintains: Buy
Price Target: $50 → $48
Current: $4.66
Upside: +930.04%
CervoMed
Jul 25, 2024
Maintains: Buy
Price Target: $65
Current: $9.64
Upside: +574.27%
Jun 20, 2024
Maintains: Buy
Price Target: $107 → $113
Current: $85.64
Upside: +31.95%
Jun 13, 2024
Downgrades: Hold
Price Target: $10 → $1
Current: $0.31
Upside: +227.87%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $11.31
Upside: +76.83%
May 2, 2024
Maintains: Buy
Price Target: $154 → $164
Current: $123.29
Upside: +33.02%
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $6.54
Upside: +297.55%
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $4.91
Upside: +246.23%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $16.27
Upside: +102.83%
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $156.00
Upside: +95.51%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $46.83
Upside: +220.31%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $17.03
Upside: -